DUBLIN – Shares in Pharming Group fell 21 percent Wednesday on news that the FDA issued a complete response letter to its supplementary BLA for Ruconest (conestat alfa) for preventing hereditary angioedema (HAE) attacks. The agency has requested an additional clinical trial to allow for further evaluation of the drug's effectiveness in the prophylactic setting.